HK Stock Market Move | IMPACT THERAP-B(07630) rose nearly 4% in the closing session. Its core product Sennapali was included in medical insurance in December last year.

IMPACT THERAP-B (07630) rose by nearly 4% at the close, rising 3.93% as of the time of publication, to HK$39.66, with a turnover of HK$138.225 million. Public information shows that Yingpai Pharmaceutical is a pharmaceutical company focusing on the development of precision anti-cancer drugs in the domestic synthetic lethal pathway, with a layout of one commercialized product + four clinical stage products + seven pre-clinical stage products. The company's core product, cenaparib, is a self-developed PARP1/2 inhibitor, which was approved in January 2025 for first-line maintenance treatment for all populations of ovarian cancer in China, and included in medical insurance in December 2025, with rapid commercialization progress. Guotou Securities International pointed out that Yingpai Pharmaceutical is a domestic pharmaceutical company in the synthetic lethal pathway, and has reached strategic cooperation with Eikon and Huadong Medicine. Its core product, Cenaparib, has been included in medical insurance. In the short term, attention can be paid to its medical insurance volume and the progress of EMA market application approval. In the long term, other clinical data readouts of pipeline and commercialization progress can be considered.